These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 34873108)
1. Factors affecting surgical decision-making in carriers of BRCA1/2 pathogenic variants undergoing risk-reducing surgery at a dedicated hereditary ovarian cancer clinic. Jacobson MR; Walker M; Ene GEV; Firestone C; Bernardini MQ; Allen L; Huszti E; Sobel M Menopause; 2021 Dec; 29(2):151-155. PubMed ID: 34873108 [TBL] [Abstract][Full Text] [Related]
2. Satisfaction with prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers is very high and little dependent on the participants' characteristics at surgery: a prospective study. Grandi G; Sammarini M; Cortesi L; Toss A; Botticelli L; Varliero F; Sighinolfi G; Barbieri E; Facchinetti F Menopause; 2021 Feb; 28(3):263-270. PubMed ID: 33534430 [TBL] [Abstract][Full Text] [Related]
3. Bilateral salpingectomy with delayed oophorectomy for ovarian cancer risk reduction: A pilot study in women with BRCA1/2 mutations. Nebgen DR; Hurteau J; Holman LL; Bradford A; Munsell MF; Soletsky BR; Sun CC; Chisholm GB; Lu KH Gynecol Oncol; 2018 Jul; 150(1):79-84. PubMed ID: 29735278 [TBL] [Abstract][Full Text] [Related]
5. The effect of personal medical history and family history of cancer on the uptake of risk-reducing salpingo-oophorectomy. van der Aa JE; Hoogendam JP; Butter ES; Ausems MG; Verheijen RH; Zweemer RP Fam Cancer; 2015 Dec; 14(4):539-44. PubMed ID: 26264902 [TBL] [Abstract][Full Text] [Related]
6. Uptake of risk-reducing salpingo-oophorectomy among female BRCA mutation carriers: experience at the National Cancer Center of Korea. Kim SI; Lim MC; Lee DO; Kong SY; Seo SS; Kang S; Lee ES; Park SY J Cancer Res Clin Oncol; 2016 Jan; 142(1):333-40. PubMed ID: 26438354 [TBL] [Abstract][Full Text] [Related]
7. Association of Risk-Reducing Salpingo-Oophorectomy With Breast Cancer Risk in Women With BRCA1 and BRCA2 Pathogenic Variants. Choi YH; Terry MB; Daly MB; MacInnis RJ; Hopper JL; Colonna S; Buys SS; Andrulis IL; John EM; Kurian AW; Briollais L JAMA Oncol; 2021 Apr; 7(4):585-592. PubMed ID: 33630024 [TBL] [Abstract][Full Text] [Related]
8. Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study. Harmsen MG; Arts-de Jong M; Hoogerbrugge N; Maas AH; Prins JB; Bulten J; Teerenstra S; Adang EM; Piek JM; van Doorn HC; van Beurden M; Mourits MJ; Zweemer RP; Gaarenstroom KN; Slangen BF; Vos MC; van Lonkhuijzen LR; Massuger LF; Hermens RP; de Hullu JA BMC Cancer; 2015 Aug; 15():593. PubMed ID: 26286255 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of a patient decision aid for BRCA1/2 pathogenic variant carriers choosing an ovarian cancer prevention strategy. Steenbeek MP; van Bommel MHD; Harmsen MG; Hoogerbrugge N; van Doorn HC; Keurentjes JHM; van Beurden M; Zweemer RP; Gaarenstroom KN; Penders CGJ; Brood-van Zanten MMA; Vos MC; Piek JM; van Lonkhuijzen LRCW; Apperloo MJA; Coppus SFPJ; IntHout J; de Hullu JA; Hermens RPMG Gynecol Oncol; 2021 Nov; 163(2):371-377. PubMed ID: 34456057 [TBL] [Abstract][Full Text] [Related]
10. Uptake of screening and risk-reducing recommendations among women with hereditary breast and ovarian cancer syndrome due to pathogenic BRCA1/2 variants evaluated at a large urban comprehensive cancer center. Assad H; Levitin M; Petrucelli N; Manning M; Thompson HS; Chen W; Jang H; Simon MS Breast Cancer Res Treat; 2024 Jul; 206(2):261-272. PubMed ID: 38605155 [TBL] [Abstract][Full Text] [Related]
11. Association of Salpingectomy With Delayed Oophorectomy Versus Salpingo-oophorectomy With Quality of Life in BRCA1/2 Pathogenic Variant Carriers: A Nonrandomized Controlled Trial. Steenbeek MP; Harmsen MG; Hoogerbrugge N; de Jong MA; Maas AHEM; Prins JB; Bulten J; Teerenstra S; van Bommel MHD; van Doorn HC; Mourits MJE; van Beurden M; Zweemer RP; Gaarenstroom KN; Slangen BFM; Brood-van Zanten MMA; Vos MC; Piek JMJ; van Lonkhuijzen LRCW; Apperloo MJA; Coppus SFPJ; Massuger LFAG; IntHout J; Hermens RPMG; de Hullu JA JAMA Oncol; 2021 Aug; 7(8):1203-1212. PubMed ID: 34081085 [TBL] [Abstract][Full Text] [Related]
12. Factors affecting the decision to undergo risk-reducing salpingo-oophorectomy among women with BRCA gene mutation. Kim D; Kang E; Hwang E; Sun Y; Hwang Y; Yom CK; Kim K; No JH; Kim YB; Kim SW Fam Cancer; 2013 Dec; 12(4):621-8. PubMed ID: 23504064 [TBL] [Abstract][Full Text] [Related]
13. High-Grade Serous Carcinoma at Risk-Reducing Salpingo-Oophorectomy in Asymptomatic Carriers of Stroot IAS; Brouwer J; Bart J; Hollema H; Stommel-Jenner DJ; Wagner MM; van Doorn HC; de Hullu JA; Gaarenstroom KN; Beurden M; van Lonkhuijzen LRCW; Slangen BFM; Zweemer RP; Gómez Garcia EB; Ausems MGEM; Boere IA; van Engelen K; van Asperen CJ; Schmidt MK; Wevers MR; de Bock GH; Mourits MJE; J Clin Oncol; 2023 May; 41(14):2523-2535. PubMed ID: 36809028 [TBL] [Abstract][Full Text] [Related]
14. Comparing Coordinated Versus Sequential Salpingo-Oophorectomy for BRCA1 and BRCA2 Mutation Carriers With Breast Cancer. S Chapman J; Roddy E; Panighetti A; Hwang S; Crawford B; Powell B; Chen LM Clin Breast Cancer; 2016 Dec; 16(6):494-499. PubMed ID: 27495996 [TBL] [Abstract][Full Text] [Related]
15. Systematic review of acceptability, cardiovascular, neurological, bone health and HRT outcomes following risk reducing surgery in BRCA carriers. Gaba F; Manchanda R Best Pract Res Clin Obstet Gynaecol; 2020 May; 65():46-65. PubMed ID: 32192936 [TBL] [Abstract][Full Text] [Related]
16. TUBectomy with delayed oophorectomy as an alternative to risk-reducing salpingo-oophorectomy in high-risk women to assess the safety of prevention: the TUBA-WISP II study protocol. Steenbeek MP; van Bommel MHD; intHout J; Peterson CB; Simons M; Roes KCB; Kets M; Norquist BM; Swisher EM; Hermens RPMG; ; Lu KH; de Hullu JA Int J Gynecol Cancer; 2023 Jun; 33(6):982-987. PubMed ID: 37045546 [TBL] [Abstract][Full Text] [Related]
17. Patient perspectives on risk-reducing salpingectomy with delayed oophorectomy for ovarian cancer risk-reduction: A systematic review of the literature. Perez L; Webster E; Bull L; Brewer JT; Ahsan MD; Lin J; Levi SR; Cantillo E; Chapman-Davis E; Holcomb K; Rosenberg SM; Frey MK Gynecol Oncol; 2023 Jun; 173():106-113. PubMed ID: 37116391 [TBL] [Abstract][Full Text] [Related]
18. Clinical and pathological outcomes of risk-reducing salpingo-oophorectomy for Japanese women with hereditary breast and ovarian cancer. Nomura H; Ikki A; Fusegi A; Omi M; Aoki Y; Netsu S; Tanigawa T; Matoda M; Okamoto S; Omatsu K; Nakajima T; Ueki A; Tonooka A; Kanao H Int J Clin Oncol; 2021 Dec; 26(12):2331-2337. PubMed ID: 34453642 [TBL] [Abstract][Full Text] [Related]
19. Uptake Rate of Risk-Reducing Salpingo-Oophorectomy and Surgical Outcomes of Female Germline Lim H; Kim SI; Hyun S; Lee GB; Seol A; Lee M Yonsei Med J; 2021 Dec; 62(12):1090-1097. PubMed ID: 34816639 [TBL] [Abstract][Full Text] [Related]
20. Study on the psychosocial aspects of risk-reducing salpingo-oophorectomy (RRSO) in BRCA1/2 mutation carriers in Japan: a preliminary report. Shigehiro M; Kita M; Takeuchi S; Ashihara Y; Arai M; Okamura H Jpn J Clin Oncol; 2016 Mar; 46(3):254-9. PubMed ID: 26685323 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]